Food and Drug Administration

FDA approves gene therapy to fix mutations that can lead to blindness

FDA approves gene therapy to fix mutations that can lead to blindness

In a decision that accelerates a new era for gene therapy, the Food and Drug Administration on Tuesday approved a DNA-altering medication that can reverse an inherited form of progressive blindness.

The FDA’s blessing makes Luxturna, a treatment for retinal dystrophy caused by a specific genetic mutation, the first gene therapy cleared for use in the U.S. to treat a genetic disease other than cancer.

Tuesday’s announcement marks the third time in five months...

EDITION: California | U.S. & World
60°